New Market Report: Oman Pharmaceuticals & Healthcare Report Q3 2014

From: Fast Market Research, Inc.
Published: Tue Jun 10 2014


Oman's strong demand for patented innovative drugs, driven by its traditional wealth, especially among the sizeable expatriate community, will continue to attract multinational company investment. Although a relatively small market in comparison with the rest of the Gulf Cooperation Council, high growth rate estimates over the next decade, the country's growing and ageing population and a rapid increase in non-communicable diseases provide opportunities for high returns on investment.

Headline Expenditure Projections

* Pharmaceuticals: OMR175mn (USD455mn) in 2013 to OMR192mn (USD505mn) in 2014; 9.5% in local currency terms and 11.0% in US dollar terms. Forecast broadly in line with Q214.
* Healthcare: OMR781mn (USD2.03bn) in 2013 to OMR860mn (USD2.26bn) in 2014; +10.1% in local currency terms and +11.5 in US dollar terms. Forecast revised slightly upwards due to macroeconomic changes.

Risk/Reward Rating

Full Report Details at
- http://www.fastmr.com/prod/829943_oman_pharmaceuticals_healthcare_report_q3_2014.aspx?afid=301

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q314, Oman's Pharmaceutical Risk/Reward Rating (RRR) scores 49.3 out of 100, which has seen the country move up two positions to 9th in the Middle East and Africa matrix. This is on account of receiving a higher score for its pharmaceutical market size (an industry rewards component) and economic diligence (a country rewards component).

Key Trends And Developments

In April 2014, the undersecretary of the Ministry of Health for Planning Affairs, Al Talib Al Hinai, said construction of the government-funded medical city in Batnah, near Muscat, was expected to begin in the near future and will be completed in 2020. According to Al Hinai the project is in the first stage of choosing a project manager and the tendering process for construction will start soon. The medical city will consist of five hospitals, namely a general...

The Oman Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Oman to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »